bromoethyl tert-butyl sulfide | 5755-60-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: bromoethyl tert-butyl sulfide
• 英文别名: 2-tert-Butylmercapto-ethylbromid；2-[(2-bromoethyl)sulfanyl]-2-methylpropane；2-(2-bromoethylsulfanyl)-2-methylpropane
• CAS: 5755-60-2
• 化学式: C₆H₁₃BrS
• mdl: MFCD12172032
• 分子量: 197.139
• InChiKey: HPXSZQNSRRWXRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  bromoethyl tert-butyl sulfide 在 sodium hydroxide 、 双氧水 、 乙酸酐 作用下， 以 乙醇 、 溶剂黄146 为溶剂， 生成 2-<2-tert-Butylsulfonyl-ethylamino>-ethyl-hydrogenthiosulfat
  参考文献：
  名称：

  的合成Ñ单取代的小号氨基乙基氢硫代硫酸盐与砜取代

  摘要：

  三种合成方法中描述了给Ñ单取代的小号，其中氨基乙基氢硫代硫酸盐ñ -取代含有砜基团。

  DOI：

  10.1039/j39660000645
• 作为产物：
  描述：

  2-(叔丁硫基)乙醇 在 三溴化磷 作用下， 以 氯仿 为溶剂， 生成 bromoethyl tert-butyl sulfide
  参考文献：
  名称：

  的合成Ñ单取代的小号氨基乙基氢硫代硫酸盐与砜取代

  摘要：

  三种合成方法中描述了给Ñ单取代的小号，其中氨基乙基氢硫代硫酸盐ñ -取代含有砜基团。

  DOI：

  10.1039/j39660000645

文献信息

• Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
  申请人：——

  公开号：US20040072802A1

  公开（公告）日：2004-04-15

  The present application describes novel &bgr;-amino acid derivatives of formula I: 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, U a , X a , Y a , Z a , R 1 , R 2 , R 3 , R 4 , and R 4a are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.

  本申请描述了式I的新颖β-氨基酸衍生物：1或其药用可接受的盐或前药形式，其中A、X、Z、Ua、Xa、Ya、Za、R1、R2、R3、R4和R4a在本规范中有定义，这些衍生物可用作金属蛋白酶和/或TNF-α抑制剂。
• DRUG DELIVERY CONJUGATES OF TERTIARY AMINE CONTAINING DRUGS
  申请人：ENDOCYTE, INC.

  公开号：US20180125992A1

  公开（公告）日：2018-05-10

  The present disclosure relates to conjugates of tertiary amine containing drugs. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making, and methods of using the same.

  本公开涉及含有三级胺的药物的共轭物。本公开还涉及所述共轭物的制药组合物、制备方法和使用方法。
• Largazole and Analogues with Modified Metal-Binding Motifs Targeting Histone Deacetylases: Synthesis and Biological Evaluation
  作者：Pravin Bhansali、Christin L. Hanigan、Robert A. Casero、L. M. Viranga Tillekeratne

  DOI：10.1021/jm200432a

  日期：2011.11.10

  The histone deacetylase inhibitor largazole 1 was synthesized by a convergent approach that involved several efficient and high yielding single pot multistep protocols. Initial attempts using tert-butyl as thiol protecting group proved problematic, and synthesis was accomplished by switching to the trityl protecting group. This synthetic protocol provides a convenient approach to many new largazole analogues. Three side chain analogues with multiple heteroatoms for chelation with Zn2+ were synthesized, and their biological activities were evaluated. They were less potent than largazole 1 in growth inhibition of HCT116 colon carcinoma cell line and in inducing increases in global H3 acetylation. Largazole 1 and the three side chain analogues had no effect on HDAC6, as indicated by the lack of increased acetylation of alpha-tubulin.
• Does a 1,4-hydrogen shift occur in .beta.-(alkylthio)ethyl radicals?
  作者：D. Casarini、L. Grossi、L. Lunazzi、G. Placucci

  DOI：10.1021/jo00205a032

  日期：1985.3
• [EN] METAL COMPLEXES FOR USE IN BORON NEUTRON CAPTURE THERAPY<br/>[FR] COMPLEXES METALLIQUES DESTINES A ETRE UTILISES EN BORONEUTROTHERAPIE
  申请人：UNIV ADELAIDE

  公开号：WO2003006434A1

  公开（公告）日：2003-01-23

  A metal complex of formula (I): [(L)M-(X)-R]m-(carborane)n...(I) or a therapeutically acceptable salt thereof characterized in that; -M represents a metal selected from the late transition group metals; -L represents ligand groups each connected to the metal sufficient to complete the coordination shell of the atom, wherein the ligand groups are the same or different and are each independently selected from the group consisting of halide; NR1R2R3 in which R?1, R2 and R3¿ may be the same or different and are and may be alkyl, aryl, ester, ether, carboxy or alkoxy; carboxylate, pyridinyl or wherein a number of ligand groups taken together form a 2,2`-bipyridine,2,2`:6,2''-terpyridine or 1,10-phenanthroline ring system; -X represents a Lewis base; -R represents an organic group connecting the Lewis base to the carborane moiety; -wherein carborane represents a dicarba-dodecarborane of the formula (C¿2?B10H10), or a substituted or functionalised derivative thereof; and -m and n are 1-4. Complexes of the invention, prepared with the ?10¿B isotope are proposed for use in boron neutron capture therapy.